{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:11:19Z","timestamp":1791090679812,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.critrevonc.2013.12.011","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T15:17:54Z","timestamp":1387293474000},"page":"98-111","source":"Crossref","is-referenced-by-count":81,"title":["Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?"],"prefix":"10.1016","volume":"91","author":[{"given":"Ilaria","family":"Marech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Introna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Francesco","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo Damiano","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0005","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2740","article-title":"Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study","volume":"11","author":"Tebib","year":"2009","journal-title":"Arthritis Research & Therapy"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.12.011_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/vr.c6030","article-title":"Clinical trial on the efficacy of masitinib in canine IBD","volume":"167","author":"Procoli","year":"2010","journal-title":"Veterinary Record"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_sbref0015a","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1398-9995.2009.02122.x","article-title":"Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_sbref0015b","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3164.2012.01088.x","article-title":"Systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008\u20132011 update","volume":"24","author":"Olivry","year":"2013","journal-title":"Veterinary Dermatology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2013.03.005","article-title":"A model of study for human cancer: spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies","author":"Ranieri","year":"2013","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.12.011_bib0030","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0035","doi-asserted-by":"crossref","first-page":"e9430","DOI":"10.1371\/journal.pone.0009430","article-title":"Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model","volume":"5","author":"Humbert","year":"2010","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.12.011_bib0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0195-5616(03)00003-2","article-title":"Mast cell tumors in the dog","volume":"33","author":"London","year":"2003","journal-title":"Veterinary Clinics of North America: Small Animal Practice"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2012.11.018","article-title":"Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study","author":"Takeuchi","year":"2013","journal-title":"Veterinary Journal"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.12.011_bib0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1939-1676.1999.tb01468.x","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor\u201441 cases (1992\u20131997)","volume":"13","author":"Thamm","year":"1999","journal-title":"Journal of Veterinary Internal Medicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.12.011_bib0060","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-08-0067","article-title":"Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors","volume":"6","author":"Letard","year":"2008","journal-title":"Molecular Cancer Research"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.12.011_bib0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of KIT are associated with higher grade mast cell tumors in dogs","volume":"39","author":"Zemke","year":"2002","journal-title":"Veterinary Pathology"},{"issue":"23","key":"10.1016\/j.critrevonc.2013.12.011_bib0070","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1007\/s00018-004-4273-y","article-title":"Kit as a human oncogenic tyrosine kinase","volume":"61","author":"Kitamura","year":"2004","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.12.011_bib0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Experimental Hematology"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0080","first-page":"923","article-title":"Diagnostic relevance of overexpressions of PKC-? and DOG-1 and KIT\/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases","volume":"32","author":"Kim","year":"2012","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1582-4934.2008.00355.x","article-title":"VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model","volume":"13","author":"Patruno","year":"2009","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.12.011_bib0090","first-page":"1189","article-title":"The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy","volume":"10","author":"Ranieri","year":"2003","journal-title":"Oncology Reports"},{"issue":"3-4","key":"10.1016\/j.critrevonc.2013.12.011_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vetimm.2010.05.009","article-title":"Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines","volume":"137","author":"Takeuchi","year":"2010","journal-title":"Veterinary Immunology and Immunopathology"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_bib0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","article-title":"Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)","volume":"46","author":"Le Cesne","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.12.011_bib0105","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2011-02-338228","article-title":"Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia","volume":"119","author":"Nick","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.lungcan.2007.01.029","article-title":"Prognostic value of KIT expression in small cell lung cancer","volume":"56","author":"L\u00f3pez-Martin","year":"2007","journal-title":"Lung Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2013.12.011_bib0115","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2012.290","article-title":"C-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/\u00df-catenin-ATP-binding cassette G2 signaling","volume":"32","author":"Chau","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.12.011_bib0120","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1593\/neo.08618","article-title":"C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis","volume":"10","author":"Wiesner","year":"2008","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2006.12.006","article-title":"Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy","volume":"69","author":"Bajaj","year":"2007","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0130","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/JTO.0b013e318200f9ad","article-title":"Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer","volume":"6","author":"Huang","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2013.05.009","article-title":"Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review","author":"Ranieri","year":"2013","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0140","unstructured":"RichmanChemicalCustom Solutions. www.RichmanChemical.com."},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0145","unstructured":"ChemicalBoock. www.chemicalbook.com\/ChemicalProductProperty."},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0150","unstructured":"Masitinib Mesylate \u2013 NCI Drug Dictionary \u2013 National Cancer Institute. www.cancer.gov\/drugdictionary?cdrid=629109."},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_bib0155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11259-009-9231-6","article-title":"Pharmacokinetics of masitinib in cats","volume":"33","author":"Bellamy","year":"2009","journal-title":"Veterinary Research Communications"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0160","unstructured":"U.S. Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FO IADrugSummaries\/UCM245243.pdf."},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0165","unstructured":"Masivet \u2013 European Drugs Reference Encyclopedia. http:\/\/www.theodora.com\/drugs\/eu\/masivet_veterinary.html."},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0170","unstructured":"Dog Aware. http:\/\/www.dogaware.com\/health\/cancer.html#newmastcell."},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0175","unstructured":"VCS Veterinary Cancer Society. http:\/\/www.vetcancersociety.org\/."},{"issue":"13","key":"10.1016\/j.critrevonc.2013.12.011_bib0180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.12.011_bib0185","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2174\/092986712799320718","article-title":"Hot topic: targeting tumor angiogenesis: an update","volume":"19","author":"Ranieri","year":"2012","journal-title":"Current Medicinal Chemistry"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.12.011_bib0190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14728222.2012.725047","article-title":"Tumor endothelial markers as a target in cancer","volume":"16","author":"Ribatti","year":"2012","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.12.011_bib0195","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.12.011_bib0200","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/092986712799320736","article-title":"Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development","volume":"19","author":"Ranieri","year":"2012","journal-title":"Current Medicinal Chemistry"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.12.011_bib0205","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/j.1460-2075.1991.tb07784.x","article-title":"Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase","volume":"10","author":"Reith","year":"1991","journal-title":"EMBO Journal"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0210","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V85.1.66.bloodjournal85166","article-title":"Soluble kit receptor in human serum","volume":"85","author":"Wypych","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.12.011_bib0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/cyto.2001.0907","article-title":"The fifth immunoglobulin-like domain of the kit receptor is required for proteolytic cleavage from the cell surface","volume":"15","author":"Broudy","year":"2001","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.12.011_bib0220","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood.V84.10.3465.3465","article-title":"Expression of stem cell factor and c-kit in human neuroblastoma The Children's Cancer Group","volume":"84","author":"Cohen","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1023\/A:1018851415704","article-title":"Expression of proto-oncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines","volume":"43","author":"Hassan","year":"1998","journal-title":"Digestive Disease and Sciences"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.12.011_bib0230","first-page":"769","article-title":"Coexpression of the c-kit and stem cell factor genes in breast carcinomas","volume":"6","author":"Hines","year":"1995","journal-title":"Cell Growth & Differentiation"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.12.011_bib0235","first-page":"3049","article-title":"Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors","volume":"54","author":"Inoue","year":"1994","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.12.011_bib0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcpa.2012.01.011","article-title":"Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours","volume":"147","author":"Giantin","year":"2012","journal-title":"Journal of Comparative Pathology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0245","first-page":"185","article-title":"VEGF expression in dog mastocytoma","volume":"114","author":"Mederle","year":"2011","journal-title":"Revista medico-chirurgicala a Societatii de Medici siNaturalisti din Iasi"},{"issue":"16","key":"10.1016\/j.critrevonc.2013.12.011_bib0250","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic","volume":"13","author":"Ranieri","year":"2006","journal-title":"Current Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0255","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncponc1037","article-title":"Drug Insight: gastrointestinal stromal tumors (GIST)\u2014the solid tumor model for cancer-specific treatment","volume":"5","author":"Sleijfer","year":"2008","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0265","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_bib0270","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.12.011_bib0275","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/labinvest.3700466","article-title":"Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumours","volume":"86","author":"Rubin","year":"2006","journal-title":"Laboratory Investigation"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.12.011_bib0280","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.12.011_bib0285","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1398-9995.2012.02833.x","article-title":"NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation","volume":"67","author":"Hadzijusufovic","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0290","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1746-6148-8-96","article-title":"Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes","volume":"8","author":"Klopfleisch","year":"2012","journal-title":"BMC Veterinary Research"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.12.011_bib0295","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ng1423","article-title":"Active genes dynamically colocalize to shared sites of ongoing transcription","volume":"36","author":"Osborne","year":"2004","journal-title":"Nature Genetics"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/org.4.2.5853","article-title":"The what, where, when and how of Wnt\/beta-catenin signaling in pancreas development","volume":"4","author":"Murtaugh","year":"2008","journal-title":"Organogenesis"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tvjl.2011.01.001","article-title":"Masitinib as a chemosensitizer of canine tumor cell lines: proof of concept study","volume":"191","author":"Thamm","year":"2012","journal-title":"Veterinary Journal"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0310","doi-asserted-by":"crossref","DOI":"10.1111\/jvp.12039","article-title":"Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein","author":"Zandvliet","year":"2013","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0315","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1476-5829.2012.00335.x","article-title":"In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines","volume":"10","author":"Lyles","year":"2012","journal-title":"Veterinary and Comparative Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1476-5829.2011.00291.x","article-title":"Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells","volume":"10","author":"Lawrence","year":"2012","journal-title":"Veterinary and Comparative Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.12.011_bib0325","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/CAD.0b013e32836002ba","article-title":"Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells","volume":"24","author":"Fahey","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.12.011_bib0330","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2460\/ajvr.71.11.1354","article-title":"Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors","volume":"71","author":"Hahn","year":"2010","journal-title":"American Journal of Veterinary Research"},{"issue":"13","key":"10.1016\/j.critrevonc.2013.12.011_bib0335","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","article-title":"Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers","volume":"45","author":"Soria","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.12.011_bib0340","series-title":"ASCO Gastrointestinal Cancers Symposium","article-title":"Overall survival benefit with masitinib mesylate in imatinib-na\u00efve locally advanced or metastatic gastro-intestinal stromal tumor (GIST): 4 years follow-up of the French Sarcoma Group phase II trial","author":"Blay","year":"2011"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2013.12.011_bib0345","article-title":"Masitinib mesylate in imatinib-resistant advanced GIST: a randomized phase II trial","volume":"30.","author":"Adenis","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0350","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00280-010-1299-8","article-title":"Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"66","author":"Mitry","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.12.011_bib0355","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501\u2013502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"European Journal of Haematology"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_bib0360","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.12.011_bib0365","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/10428190412331272695","article-title":"A leukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V","volume":"45","author":"Noack","year":"2004","journal-title":"Leukemia & Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.12.011_bib0370","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.12.011_bib0375","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis\u2014in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leukemia Research"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.12.011_bib0380","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.12.011_bib0385","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2011.354","article-title":"Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A","volume":"26","author":"Spector","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.12.011_bib0390","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/leu.2011.354","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0395","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.12.011_bib0400","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0405","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nri1782","article-title":"Integrated signalling pathways for mast-cell activation","volume":"6","author":"Gilfillan","year":"2006","journal-title":"Nature Reviews Immunology"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.12.011_bib0410","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0415","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2340\/00015555-1196","article-title":"Stevens\u2013Johnson Syndrome induced by masitinib","volume":"92","author":"Chaigne","year":"2012","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0420","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","article-title":"Stevens\u2013Johnson syndrome after treatment with STI571: a case report","volume":"117","author":"Hsiao","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"9440","key":"10.1016\/j.critrevonc.2013.12.011_bib0425","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"Suppl. 34","key":"10.1016\/j.critrevonc.2013.12.011_bib0430","article-title":"Masitinib in nonresectable pancreatic cancer: results of a phase III randomized placebo-controlled trial","volume":"30","author":"Deplanque","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.12.011_bib0435","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1016\/j.critrevonc.2013.12.011_bib0440","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1016\/j.critrevonc.2013.12.011_bib0445","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.12.011_bib0450","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.12.011_bib0455","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10637-010-9592-2","article-title":"Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib","volume":"30","author":"Lassau","year":"2012","journal-title":"Investigational New Drugs"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:02:20Z","timestamp":1716303740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813002667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1040842813002667"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}